| abstract |
The present invention provides a purinone compound as a Breton-type tyrosine kinase (Btk) inhibitor, and a pharmaceutical composition comprising the compound. A compound having a purinone skeleton, a compound represented by the following formula, and a pharmaceutically acceptable metabolite, pharmaceutically acceptable solvate, pharmaceutically acceptable salt or pharmaceutically acceptable metabolite thereof. Pharmaceutically acceptable prodrugs. 【Selection chart】 None |